#United States #New York #Levi & Korsinsky #Humacyte #Inc. #securities lawsuit

Levi & Korsinsky Announces Class Action Against Humacyte, Inc.

Levi & Korsinsky, LLP has reached out to investors of Humacyte, Inc. (NASDAQ: HUMA) to inform them about a class action lawsuit that is underway. This legal initiative aims to address the alleged securities fraud that impacted shareholders based on events between May 10, 2024, and October 17, 2024. Investors are encouraged to act swiftly, as the deadline for joining this class action is set for January 17, 2025.

Background of the Case

The class action lawsuit filed by Levi & Korsinsky highlights a series of misrepresentations made by the company regarding its operations and compliance with manufacturing standards. According to the complaint, Humacyte's facility in Durham, North Carolina allegedly failed to meet good manufacturing practices, which included crucial quality assurance and microbial testing processes. These oversights raised significant concerns about the company’s ability to gain FDA approval for its acellular tissue engineered vessel designed for vascular trauma applications.

Furthermore, the lawsuit asserts that the delay in the FDA's review of its biologics license application is expected as Humacyte works to remediate these significant deficiencies. As a result, the positive claims made by core executives about the company's future operations and market prospects were said to be materially misleading and lacking a reasonable basis.

What Investors Should Know

If you are a shareholder who suffered losses during the specified period, now is the time to consider your options. The class action lawsuit allows aggrieved investors to seek compensation without incurring out-of-pocket costs. You do not need to take on the role of lead plaintiff to share in any potential recovery that results from this case.

Levi & Korsinsky has a strong track record of securing settlements for its clients, and its expertise in complex securities litigation could be crucial for affected investors. They have been recognized as one of the top securities litigation firms in the United States over the past seven years and have helped recover hundreds of millions of dollars for shareholders.

For investors looking to join this class action, you can reach out directly to Levi & Korsinsky. Interested parties can find further information and request to be contacted by a representative through the firm's website or by reaching out to Joseph E. Levi via email or phone.

Contact Information

For more detailed inquiries regarding the class action or to sign up, you can contact:

• - Joseph E. Levi, Esq.

Email: [email protected]
Phone: (212) 363-7500

It is crucial to act quickly, as the window for participation closes soon. Do not miss your opportunity to be part of this class action against Humacyte, Inc.

Conclusion

The unfolding situation surrounding Humacyte, Inc. carries significant implications for its investors amidst allegations of serious manufacturing and oversight failures. If you believe your investment in Humacyte was compromised due to these issues, consider joining the class action lawsuit led by Levi & Korsinsky today. Time is of the essence, and the deadline of January 17, 2025, is fast approaching.

Stay informed and protect your rights as a shareholder in this developing case.